AXSM - 1 Risky Growth Stock Wall Street Says Is Poised for a 47% Rally
2023-04-20 06:20:00 ET
Sometimes the experts get their growth stock predictions right, and sometimes they miss the mark. An average of Wall Street analyst forecasts suggests share prices of Axsome Therapeutics (NASDAQ: AXSM) could rise by 47% over the next 12 months. But so far this year, the stock price is instead down by 6.6%.
That raises the question: Will this biotech startup's stock rally like there's no tomorrow in the near term, or are new shareholders bound for disappointment? The answer depends on which arguments for and against you find most credible. Let's take a look at some of them in more detail and see which way the answer leans.
Wall Street's consensus estimate about Axsome's future stock price isn't too outrageous, since it has a couple of powerful new drivers of revenue growth, and more on the way, assuming that its proposed drug therapies finish clinical trials successfully.
For further details see:
1 Risky Growth Stock Wall Street Says Is Poised for a 47% Rally